These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11456044)

  • 21. Do we need a checklist for reporting the results of diagnostic test evaluations? The STARD proposal.
    Gatsonis C
    Acad Radiol; 2003 Jun; 10(6):599-600. PubMed ID: 12809411
    [No Abstract]   [Full Text] [Related]  

  • 22. Monitoring clinical trials.
    Sharples K; Fleming TR; MacMahon S; Moore A; Reid I; Scoggins B
    N Z Med J; 1998 Aug; 111(1072):322-5. PubMed ID: 9765633
    [No Abstract]   [Full Text] [Related]  

  • 23. Perusing the literature.
    Hawkins BS
    Control Clin Trials; 1982 Dec; 3(4):371-83. PubMed ID: 6761064
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical trial registration in physiotherapy journals: recommendations from the International Society of Physiotherapy Journal Editors.
    Costa LO; Christine Lin CW; Grossi DB; Mancini MC; Swisher AK; Cook C; Vaughn D; Elkins MR; Sheikh U; Moore A; Jull G; Craik RL; Maher CG; de Jesus Guirro RR; Marques AP; Harms M; Brooks D; Simoneau GG; Strupstad JH
    Man Ther; 2013 Feb; 18(1):1-3. PubMed ID: 23158021
    [No Abstract]   [Full Text] [Related]  

  • 25. Society of Interventional Radiology Interventional Oncology Task Force: interventional oncology research vision statement and critical assessment of the state of research affairs.
    Goldberg SN; Bonn J; Dodd G; Dupuy D; Geschwind JH; Hicks M; Hume KM; Lee FT; Lewis CA; Lencioni RA; Omary RA; Rundback JH; Silverman S; Dorfman GS;
    J Vasc Interv Radiol; 2005 Oct; 16(10):1287-94. PubMed ID: 16221897
    [No Abstract]   [Full Text] [Related]  

  • 26. Regression toward the mean in 2 x 2 crossover designs with baseline measurements.
    Grender JM; Johnson WD; Elston RC
    Stat Med; 1992 Apr; 11(6):727-41. PubMed ID: 1594812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trials.
    Smith AJ
    Med J Aust; 1984 Jun; 140(12):720-3. PubMed ID: 6727737
    [No Abstract]   [Full Text] [Related]  

  • 28. Hospital or population controls? It depends on the question.
    Miller AB
    Prev Med; 1994 May; 23(3):263-6. PubMed ID: 8078845
    [No Abstract]   [Full Text] [Related]  

  • 29. Tidal volumes in ARDS and meta-analysis.
    Stefanec T
    Am J Respir Crit Care Med; 2003 Mar; 167(6):934; author reply 934-5. PubMed ID: 12653109
    [No Abstract]   [Full Text] [Related]  

  • 30. Animal experiments under fire for poor design.
    Giles J
    Nature; 2006 Dec; 444(7122):981. PubMed ID: 17183281
    [No Abstract]   [Full Text] [Related]  

  • 31. [Complementary Medicine in Oncology - difficult to claim effectiveness, quality and efficiency].
    Melchart D
    Forsch Komplementmed; 2015; 22(1):8-9. PubMed ID: 25824398
    [No Abstract]   [Full Text] [Related]  

  • 32. Design of oncology clinical trials: a review.
    Ananthakrishnan R; Menon S
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):144-53. PubMed ID: 23623356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical trials; the admissibility of generalization of outcome].
    Lankhorst GJ
    Ned Tijdschr Geneeskd; 1987 Nov; 131(47):2118-20. PubMed ID: 3683648
    [No Abstract]   [Full Text] [Related]  

  • 34. Exploring the use of the sham design for interventional trials: implications for endoscopic research.
    Wilcox CM
    Gastrointest Endosc; 2008 Jan; 67(1):123-7. PubMed ID: 18155434
    [No Abstract]   [Full Text] [Related]  

  • 35. Ocular oncology and the study of rare cancers.
    Margo CE
    Cancer Control; 2004; 11(5):283-4. PubMed ID: 15377986
    [No Abstract]   [Full Text] [Related]  

  • 36. Design of clinical trials in patients with urinary tract infections.
    Norrby SR
    Infection; 1992; 20 Suppl 3():S181-8; discussion S189-92. PubMed ID: 1490745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trial design in oncology: protocol design.
    Sullivan R
    Lancet Oncol; 2004 Dec; 5(12):759. PubMed ID: 15581549
    [No Abstract]   [Full Text] [Related]  

  • 38. The nurse as principal investigator in a pharmaceutically sponsored drug trial: considerations and challenges.
    Rosenzweig MQ; Bender CM; Brufsky AM
    Oncol Nurs Forum; 2005 Mar; 32(2):293-9. PubMed ID: 15759067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recommendations for myasthenia gravis clinical trials.
    Li HF; Gao X; Xie YC
    Muscle Nerve; 2013 Jan; 47(1):144-5. PubMed ID: 23042233
    [No Abstract]   [Full Text] [Related]  

  • 40. Study design: two standards?
    Sapira JD
    Ann Intern Med; 1985 Nov; 103(5):810. PubMed ID: 4051370
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.